Navigation Links
Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes
Date:6/26/2010

ORLANDO, Fla., June 26, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from an analysis of an integrated database of clinical studies that showed no increased risk of cardiovascular (CV) events associated with SYMLIN® (pramlintide acetate) injection use compared to a pooled comparator group treated with either placebo or rapid-acting insulin. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.

The meta-analysis included five completed, randomized, controlled clinical trials of 16 to 52 weeks' duration, and was based on the U.S. Food and Drug Administration's (FDA's) recent guidance for evaluating CV risk in new type 2 diabetes agents. The primary endpoint for this analysis was occurrence of primary major adverse CV events (MACE). The 95 percent confidence interval for the estimated risk ratio for the primary endpoint was 0.55 to 1.34.  With the upper limit below the FDA-specified threshold of 1.8, this suggests that there is no increase in CV risk associated with SYMLIN use.  

"People with diabetes are two to four times more likely to develop cardiovascular disease because of increased risk factors such as high blood pressure, lipid disorders and obesity," said Orville G. Kolterman, M.D., senior vice president, chief medical officer at Amylin. "SYMLIN is an important tool for many patients who struggle to achieve their glucose control targets, despite their best efforts with insulin. These safety analyses confirm our findings from individual clinical studies and provide additional insight into the CV safety prof
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Corgenix Receives Additional European Patent, Announces Publication of Important Clinical Study on AtherOx(R) Technology
2. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
3. Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
4. Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
5. Open Source Clinical Trials Software Featured at the 46th DIA Annual Meeting
6. Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting
7. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
8. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
9. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
10. Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting
11. Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 Freeslate, ... solutions, today announced that Lupin Limited, one of India’s ... CM Protégé PharmD System for high throughput ... India, is focused on a wide range of quality, ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled ... 2pm EST (11am PST), “Natural Language Processing: Converting Raw ... technology can turn raw, heterogeneous data into actionable knowledge ... online webinar will last approximately one hour. , Synopsis: ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... ITMN ) today announced that Dan Welch, President ... Bank of America 2008,Health Care Conference in Las Vegas ... EDT)., To access a live audio webcast of ... to the investor relations page of InterMune,s,corporate website at ...
... Mass., May 9 Inverness Medical,Innovations (Amex: ... previously announced,acquisition of Matria Healthcare, Inc. was ... of business today, May 9, 2008. Matria,headquartered ... services particularly in the areas of women,s ...
... ... earnings growth., ST. DAVID,S, Bermuda, May 9 ... quarter ended,March 31, 2008. Revenue in the quarter ended March 31, 2008 ... primary,drivers of the increase in revenue were the net sales of our ...
Cached Biology Technology:Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc. 2Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 2Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 3Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 4Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 5Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 6Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 7Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 8Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 9Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 10Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 11Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 12Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 13Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 14Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 15Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 16Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance 17
(Date:4/20/2014)... pancreatic cancers also promote drug-resistance and ultimately spur tumor ... School of Medicine have discovered a molecule, or biomarker, ... appears responsible for inducing tumor metastasis by enhancing the ... findings, published in the April 20, 2014 online issue ... new therapeutic opportunities for reversing drug resistance in a ...
(Date:4/18/2014)... of emergency contraceptive pills in Peru found that ... of substandard quality or falsified. Many pills released ... wrong active ingredient. One batch had no active ... fake drugs, researchers at the Georgia Institute of ... to quickly assess suspected counterfeit drugs and then ...
(Date:4/18/2014)... DNA adds a twist to the story of how barnyard ... April 21 in the journal Proceedings of the National ... of chickens that lived 200-2300 years ago in Europe, researchers ... may have looked far different from the chickens we know ... we associate with modern domestic chickens -- such as their ...
Breaking Biology News(10 mins):Cancer stem cells linked to drug resistance 2Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Ancient DNA offers clues to how barnyard chickens came to be 2
... funded by the Government of Canada, today announced $100,000 ... income countries worldwide to pursue bold, creative ideas to ... also announced for 17 Canadian-based projects to be implemented ... will mimic rocket technology to propel coagulant nanoparticles into ...
... is living in your gut, and what they,re doing? The ... our own cells by as many as 10 to 1 ... the food we eat this Thanksgiving to building up our ... researchers at the University of Colorado Boulder along with researchers ...
... The days of researching cell behavior by using the ... fluorescence microscopes have gone. Microscopy has now reached the ... mathematics, and a new field is emerging at the ... how scientists study fundamental questions of cell behavior. ...
Cached Biology News:Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries 2Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries 3Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries 4Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries 5Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries 6Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries 7Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries 8Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries 9Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries 10Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries 11Inspired: Canada funds 68 bold, inventive ways to improve health, save lives in developing countries 12New public gut bacteria study expected to reach around world 2New public gut bacteria study expected to reach around world 3New public gut bacteria study expected to reach around world 4A multidisciplinary approach and a new field help to understand cell behavior 2
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827...
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
... 100 g of monoclonal antibody reactive against ... of SURF1 are highest in growing cultured cells. ... c oxidase which is thought to participate in ... insertion into this subunit. Mutations of SURF1, particularly ...
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Biology Products: